ClinicalTrials.gg
CompletedNCT00783263Updated May 14, 2024Results posted

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

A Phase 3 interventional study of Comparator: rosuvastatin 5 mg + ezetimibe 10 mg and Comparator: rosuvastatin 10 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
21st of 57
440 · median 203
Started
2008
with 1 other
Phase 3
33 of 59
none open now
Registered
29th of 59
by date
Lead sponsor
6 of 59
Organon and Co

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 21st largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2008, is one of 33 in phase 3, and was the 29th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

A study to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of the addition of ezetimibe to rosuvastatin compared with doubling dose of rosuvastatin in participants treated with rosuvastatin alone and not at their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is currently taking a stable dose of lipid lowering agent(s). (if applicable) or is statin naive
  • Participant is currently taking a stable dose of lipid lowering agent(s). (if is at least moderate high risk for Coronary Heart Disease (CHD))
  • Participant is currently taking a stable dose of lipid lowering agent(s). (if is willing to maintain Therapeutic Lifestyle Changes (TLC) / American Diabetes Association(ADA) diet)

Exclusion criteria

Exclusion Criteria:

  • Participant weighs less than 100 lbs (45 kg).
  • Participant has or intolerance to ezetimibe, or rosuvastatin or any components of these medications.
  • If female, participant is pregnant or breastfeeding.
  • Participant consumes more than 2 alcoholic beverages per day.
  • Participant has been in a clinical trial within the last 30 days.
  • Participant has heart problems such as CHF, unstable angina or heart attack.
  • Participant has type 1 or 2 diabetes and has changed their medication in the last 2 months.
  • Participant has liver disease.
  • Participant is (HIV) positive.
  • Participant has a history of drug or alcohol abuse in the last year.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Rosuvastatin 5 mg + Ezetimibe 10 mg

    Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.

    Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg

  • Active comparator
    Rosuvastatin 10 mg

    Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.

    Drug: Comparator: rosuvastatin 10 mg

  • Experimental
    Rosuvastatin 10 mg + Ezetimibe 10 mg

    Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.

    Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg

  • Active comparator
    Rosuvastatin 20 mg

    Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.

    Drug: Comparator: rosuvastatin 20 mg

Interventions

  • DrugComparator: rosuvastatin 5 mg + ezetimibe 10 mg

    Drug page: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.

    Also known as: Crestor, Zetia

  • DrugRosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.

    Also known as: Crestor

  • DrugComparator: rosuvastatin 10 mg + ezetimibe 10 mg

    Drug page: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.

    Also known as: Crestor, Zetia

  • DrugRosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.

    Also known as: Crestor

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment

    The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment in participants who were administered ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum

    The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment by stratum I and stratum II in participants who were administered with ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with the doubling of the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.

    Time frame: Baseline to 6 weeks

  2. Number of Participants Who Reached Their Target LDL-C Level

    Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment.

    Time frame: 6 weeks of treatment

  3. Number of Participants in Each Stratum Who Reached Their Target LDL-C Level

    Participants in stratum I were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 5 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 10 mg daily for 6 weeks. Participants in stratum II were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 10 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 20 mg daily for 6 weeks.

    Time frame: 6 weeks of treatment

  4. Number of Participants Who Reached the LDL-C Level of <70 mg/dl

    Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.

    Time frame: 6 weeks of treatment

  5. Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl

    Participants in stratum I and in stratum II who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe to rosuvastatin (5 or 10 mg)daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg).

    Time frame: 6 weeks of treatment

  6. Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels

    Participants who were analyzed to assess the Total Cholesterol (TC), Triglycerides, High-Density Lipoprotein Cholesterol, Non High-Density Lipoprotein Cholesterol, LDL Cholesterol/HDL Cholesterol, Total Cholesterol/HDL Cholesterol, Non-HDL Cholesterol/HDL Cholesterol, Apolipoprotein B (Apo B), Apolipoprotein A-I (Apo A-I), Apolipoprotein B/Apo A-I, high-sensitivity C-reactive protein (hs-CRP)levels after 6 weeks of treatment.

    Time frame: Baseline to 6 weeks

07

Results

Posted Sep 14, 2011

Participant flow

Participant flow — Overall Study
MilestoneRosuvastatin 5 mg + Ezetimibe 10 mgRosuvastatin 10 mgRosuvastatin 10 mg + Ezetimibe 10 mgRosuvastatin 20 mg
Started9998122121
Completed9596119118
Not completed4233
Withdrew: Adverse event3021
Withdrew: Lost to follow-up1100
Withdrew: Withdrawal by subject0112

Outcome measures

PrimaryPercent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment

The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment in participants who were administered ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · percent change
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment
percent changeRosuvastatin (5 or 10 mg) + Ezetimibe 10 mgRosuvastatin (10 or 20 mg)
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment-21.57 ± 25.09-5.58 ± 25.42
Statistical analysis
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin (10 or 20 mg) · Longitudinal Data Analysis (LDA) · p = <0.001 · Mean difference (final values): -15.25 · 95% CI -19.89 to -10.60Longitudinal Data Analysis was based on a constrained LDA model with terms for treatment, time, stratum and the interaction of time by treatment.
SecondaryPercent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum

The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment by stratum I and stratum II in participants who were administered with ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with the doubling of the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · percentage change
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum
percentage changeRosuvastatin 5 mg + Ezetimibe 10 mg (Stratum I)Rosuvastatin 10 mg (Stratum I)Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II)Rosuvastatin 20 mg (Stratum II)
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum-18.57 ± 26.35-4.96 ± 22.42-24.00 ± 23.86-6.07 ± 27.65
Statistical analysis
  • Rosuvastatin 5 mg + Ezetimibe 10 mg (Stratum I) vs Rosuvastatin 10 mg (Stratum I) · Longitudinal Data Analysis (LDA) · p = <0.001 · Mean difference (final values): -12.31 · 95% CI -18.95 to -5.67Longitudinal Data Analysis was based on a constrained LDA model with terms for treatment, time and the interaction of time by treatment.
  • Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) vs Rosuvastatin 20 mg (Stratum II) · Longitudinal Data Analysis (LDA) · p = <0.001 · Mean difference (final values): -17.46 · 95% CI -23.92 to -10.99Longitudinal Data Analysis was based on a constrained LDA model with terms for treatment, time and the interaction of time by treatment.
SecondaryNumber of Participants Who Reached Their Target LDL-C Level

Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment.

Time frame:
6 weeks of treatment
Reported as:
Number · participants
Number of Participants Who Reached Their Target LDL-C Level
participantsRosuvastatin (5 or 10 mg) + Ezetimibe 10 mgRosuvastatin (10 or 20 mg)
Number of Participants Who Reached Their Target LDL-C Level13067
Statistical analysis
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin (10 or 20 mg) · Logistic Regression · p = <0.001 · Odds ratio (or): 4.5 · 95% CI 2.9 to 6.9Logistic Regression included terms for treatment, stratum and baseline LDL-C category (3 levels: \<100, 100-\<130, ≥130 mg/dL).
SecondaryNumber of Participants in Each Stratum Who Reached Their Target LDL-C Level

Participants in stratum I were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 5 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 10 mg daily for 6 weeks. Participants in stratum II were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 10 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 20 mg daily for 6 weeks.

Time frame:
6 weeks of treatment
Reported as:
Number · participants
Number of Participants in Each Stratum Who Reached Their Target LDL-C Level
participantsRosuvastatin 5 mg + Ezetimibe 10 mg (Stratum I)Rosuvastatin 10 mg (Stratum I)Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II)Rosuvastatin 20 mg (Stratum II)
Number of Participants in Each Stratum Who Reached Their Target LDL-C Level54307637
Statistical analysis
  • Rosuvastatin 5 mg + Ezetimibe 10 mg (Stratum I) vs Rosuvastatin 10 mg (Stratum I) · Logistic Regression · p = <0.001 · Odds ratio (or): 3.1 · 95% CI 1.7 to 5.8Logistic Regression included terms for treatment and baseline LDL-C category (3 levels: \<100, 100-\<130, \>=130 mg/dL).
  • Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) vs Rosuvastatin 20 mg (Stratum II) · Logistic Regression · p = <0.001 · Odds ratio (or): 6.5 · 95% CI 3.4 to 12.3Logistic Regression included terms for treatment and baseline LDL-C category (3 levels: \<100, 100-\<130, \>=130 mg/dL).
SecondaryNumber of Participants Who Reached the LDL-C Level of <70 mg/dl

Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.

Time frame:
6 weeks of treatment
Reported as:
Number · participants
Number of Participants Who Reached the LDL-C Level of <70 mg/dl
participantsRosuvastatin (5 or 10 mg) + Ezetimibe 10 mgRosuvastatin 10 or 20 mg
Number of Participants Who Reached the LDL-C Level of <70 mg/dl9638
Statistical analysis
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Logistic Regression · p = <0.001 · Odds ratio (or): 8.0 · 95% CI 4.6 to 14.0
SecondaryNumber of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl

Participants in stratum I and in stratum II who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe to rosuvastatin (5 or 10 mg)daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg).

Time frame:
6 weeks of treatment
Reported as:
Number · participants
Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl
participantsRosuvastatin 5 mg + Ezetimibe 10 mgRosuvastatin 10 mgRosuvastatin 10 mg + Ezetimibe 10 mgRosuvastatin 20 mg
Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl31126526
Statistical analysis
  • Rosuvastatin 5 mg + Ezetimibe 10 mg vs Rosuvastatin 10 mg · Logistic Regression · p = <0.001 · Odds ratio (or): 5.1 · 95% CI 2.2 to 11.8
  • Rosuvastatin 10 mg + Ezetimibe 10 mg vs Rosuvastatin 20 mg · Logistic Regression · p = <0.001 · Odds ratio (or): 11.4 · 95% CI 5.2 to 24.8
SecondaryPercent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels

Participants who were analyzed to assess the Total Cholesterol (TC), Triglycerides, High-Density Lipoprotein Cholesterol, Non High-Density Lipoprotein Cholesterol, LDL Cholesterol/HDL Cholesterol, Total Cholesterol/HDL Cholesterol, Non-HDL Cholesterol/HDL Cholesterol, Apolipoprotein B (Apo B), Apolipoprotein A-I (Apo A-I), Apolipoprotein B/Apo A-I, high-sensitivity C-reactive protein (hs-CRP)levels after 6 weeks of treatment.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · percentage change
Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels
percentage changeRosuvastatin (5 or 10 mg) + Ezetimibe 10 mgRosuvastatin 10 or 20 mg
Total Cholesterol (TC)-13.00 ± 17.51-3.76 ± 14.35
Triglycerides-5.96 ± 36.45-3.60 ± 32.83
High-Density Lipoprotein Cholesterol-0.67 ± 15.512.18 ± 13.38
Non High-Density Liproprotein Cholesterol-17.59 ± 23.55-5.29 ± 21.20
LDL Cholesterol/HDL Cholesterol-19.48 ± 27.63-6.18 ± 27.82
Total Cholesterol/HDL Cholesterol-10.57 ± 25.87-4.40 ± 18.27
Non-HDL Cholestrol/HDL Cholesterol-14.51 ± 35.39-5.31 ± 26.63
Apolipoprotein B (Apo B)-14.31 ± 18.61-4.25 ± 17.56
Apolipoprotein A-I (Apo A-I)-1.44 ± 12.491.06 ± 11.56
Apolipoprotein B/Apo A-I-11.98 ± 20.84-4.11 ± 19.61
hs-C-Reactive Protein-13.98 ± 72.19-12.82 ± 73.08
Statistical analysis
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -8.65 · 95% CI -11.59 to -5.71
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = 0.306 · Mean difference (final values): -3.10 · 95% CI -9.04 to 2.84
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = 0.111 · Mean difference (final values): -2.15 · 95% CI -4.79 to 0.49
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -11.98 · 95% CI -16.10 to -7.86
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -13.25 · 95% CI -18.36 to -8.13
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = 0.002 · Mean difference (final values): -6.45 · 95% CI -10.53 to -2.36
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = 0.001 · Mean difference (final values): -9.52 · 95% CI -15.30 to -3.75
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -9.41 · 95% CI -12.74 to -6.08
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = 0.102 · Mean difference (final values): -1.82 · 95% CI -3.99 to 0.36
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = <0.001 · Mean difference (final values): -7.54 · 95% CI -11.25 to -3.83
  • Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg · Longitudinal Data Analysis · p = 0.861 · Mean difference (final values): -1.08 · 95% CI -13.13 to 10.97

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuva 5 mg + EZ 10 mg—0/99 (0%)0/99 (0%)
Rosuva 10 mg—1/98 (1%)0/98 (0%)
Rosuva 10 mg + EZ 10 mg—0/122 (0%)0/122 (0%)
Rosuva 20 mg—1/121 (0.8%)0/121 (0%)
Most frequent serious events
Most frequent serious events
EventRosuva 5 mg + EZ 10 mgRosuva 10 mgRosuva 10 mg + EZ 10 mgRosuva 20 mg
Tendon ruptureInjury, poisoning and procedural complications0/991/980/1220/121
Sick sinus syndromeCardiac disorders0/990/980/1221/121

Baseline characteristics

Age, Customized
Age, Customized(participants)Rosuvastatin 5 mg + Ezetimibe 10 mgRosuvastatin 10 mgRosuvastatin 10 mg + Ezetimibe 10 mgRosuvastatin 20 mgTotal
< 65 years63627171267
≥ 65 years36365150173
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 5 mg + Ezetimibe 10 mgRosuvastatin 10 mgRosuvastatin 10 mg + Ezetimibe 10 mgRosuvastatin 20 mgTotal
Female35405637168
Male64586684272
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15;108(4):523-30. doi: 10.1016/j.amjcard.2011.03.079. Epub 2011 May 17. PubMed 21596364 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 4 months after primary completion. A results delay was requested in May 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
Start
Nov 2008
Primary completionActual
May 2010
CompletionActual
May 2010
Results delay requested
May 10, 2011
Results first posted
Sep 14, 2011
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00783263
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 31, 2008
Start date
Nov 2008
Primary completion
May 2010
Completion
May 2010
Results posted
Sep 14, 2011
Last update
May 14, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion